肺癌免疫治疗的前景。

Q4 Biochemistry, Genetics and Molecular Biology

Progress in Tumor Research Pub Date : 2015-01-01 Epub Date: 2015-09-04 DOI:10.1159/000437179

Anil Shanker, Mikhail M Dikov, David P Carbone

{"title":"肺癌免疫治疗的前景。","authors":"Anil Shanker, Mikhail M Dikov, David P Carbone","doi":"10.1159/000437179","DOIUrl":null,"url":null,"abstract":"Metastatic lung cancer is the most common cause of cancer mortality globally in both men and women, with 5-year survival of less than 5%. Standard treatment approaches for metastatic lung cancer are based on chemotherapy, with radiation and surgery used for local control, but these rarely result in relapse-free survivals longer than 2-3 years, although they may provide symptom relief. Thus, additional tools are needed to treat this disease. In this chapter, we discuss the various immune-based cancer treatments for lung cancer patients that are being developed, and the increasing awareness that therapies targeted at overcoming immune evasion mechanisms may be essential to clinical efficacy. ","PeriodicalId":49661,"journal":{"name":"Progress in Tumor Research","volume":"42 ","pages":"95-109"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000437179","citationCount":"3","resultStr":"{\"title\":\"Promise of Immunotherapy in Lung Cancer.\",\"authors\":\"Anil Shanker, Mikhail M Dikov, David P Carbone\",\"doi\":\"10.1159/000437179\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Metastatic lung cancer is the most common cause of cancer mortality globally in both men and women, with 5-year survival of less than 5%. Standard treatment approaches for metastatic lung cancer are based on chemotherapy, with radiation and surgery used for local control, but these rarely result in relapse-free survivals longer than 2-3 years, although they may provide symptom relief. Thus, additional tools are needed to treat this disease. In this chapter, we discuss the various immune-based cancer treatments for lung cancer patients that are being developed, and the increasing awareness that therapies targeted at overcoming immune evasion mechanisms may be essential to clinical efficacy. \",\"PeriodicalId\":49661,\"journal\":{\"name\":\"Progress in Tumor Research\",\"volume\":\"42 \",\"pages\":\"95-109\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000437179\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Tumor Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000437179\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2015/9/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Tumor Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000437179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/9/4 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 3

摘要

转移性肺癌是全球男性和女性癌症死亡的最常见原因，其5年生存率低于5%。转移性肺癌的标准治疗方法是基于化疗，放疗和手术用于局部控制，但这些方法很少导致超过2-3年的无复发生存期，尽管它们可能提供症状缓解。因此，需要更多的工具来治疗这种疾病。在本章中，我们讨论了正在开发的各种基于免疫的肺癌治疗方法，以及越来越多的人意识到针对克服免疫逃避机制的治疗可能对临床疗效至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Promise of Immunotherapy in Lung Cancer.

Metastatic lung cancer is the most common cause of cancer mortality globally in both men and women, with 5-year survival of less than 5%. Standard treatment approaches for metastatic lung cancer are based on chemotherapy, with radiation and surgery used for local control, but these rarely result in relapse-free survivals longer than 2-3 years, although they may provide symptom relief. Thus, additional tools are needed to treat this disease. In this chapter, we discuss the various immune-based cancer treatments for lung cancer patients that are being developed, and the increasing awareness that therapies targeted at overcoming immune evasion mechanisms may be essential to clinical efficacy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Progress in Tumor Research 医学-肿瘤学

CiteScore

2.50

自引率

0.00%

发文量

期刊介绍： The scientific book series ''Progress in Tumor Research'' aims to provide in depth information about important developments in cancer research. The individual volumes are authored and edited by experts to provide detailed coverage of topics selected as either representing controversial issues or belonging to areas where the speed of developments necessitates the kind of assistance offered by integrative, critical reviews.